XNASIART
Market cap1.68bUSD
Jan 10, Last price
21.81USD
1D
-1.98%
1Q
13.42%
Jan 2017
-49.16%
Name
Integra Lifesciences Holdings Corp
Chart & Performance
Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 1,541,573 -1.03% | 1,557,666 0.99% | |||||||
Cost of revenue | 827,772 | 688,548 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 713,801 | 869,118 | |||||||
NOPBT Margin | 46.30% | 55.80% | |||||||
Operating Taxes | 13,328 | 33,344 | |||||||
Tax Rate | 1.87% | 3.84% | |||||||
NOPAT | 700,473 | 835,774 | |||||||
Net income | 67,741 -62.48% | 180,550 6.79% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (275,000) | (144,153) | |||||||
BB yield | 7.86% | 3.08% | |||||||
Debt | |||||||||
Debt current | 29,815 | 52,749 | |||||||
Long-term debt | 1,834,000 | 1,734,654 | |||||||
Deferred revenue | 7,700 | 8,800 | |||||||
Other long-term liabilities | 192,240 | 129,701 | |||||||
Net debt | 1,524,009 | 763,401 | |||||||
Cash flow | |||||||||
Cash from operating activities | 139,955 | 264,469 | |||||||
CAPEX | (66,865) | (47,085) | |||||||
Cash from investing activities | (94,178) | (58,580) | |||||||
Cash from financing activities | (229,925) | (251,953) | |||||||
FCF | 628,581 | 695,776 | |||||||
Balance | |||||||||
Cash | 309,096 | 456,661 | |||||||
Long term investments | 30,710 | 567,341 | |||||||
Excess cash | 262,727 | 946,119 | |||||||
Stockholders' equity | 932,662 | 890,288 | |||||||
Invested Capital | 3,206,779 | 2,667,975 | |||||||
ROIC | 23.85% | 29.42% | |||||||
ROCE | 20.37% | 24.00% | |||||||
EV | |||||||||
Common stock shares outstanding | 80,337 | 83,516 | |||||||
Price | 43.55 -22.33% | 56.07 -16.30% | |||||||
Market cap | 3,498,676 -25.29% | 4,682,742 -18.23% | |||||||
EV | 5,022,685 | 5,446,143 | |||||||
EBITDA | 837,313 | 987,417 | |||||||
EV/EBITDA | 6.00 | 5.52 | |||||||
Interest | 51,377 | 49,594 | |||||||
Interest/NOPBT | 7.20% | 5.71% |